Artificial Disc Replacement denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for artificial disc replacement are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Artificial Disc Replacement as Not FDA-Approved

A "not FDA-approved" denial for artificial disc replacement (ADR) usually means one of three things: (1) the specific device model submitted on the claim has not received FDA clearance or approval for the spine level being treated, (2) the procedure is being proposed for an indication outside the device's cleared label, or (3) the claim was coded in a way that Humana's system could not verify clearance. This denial category is often the result of administrative mismatch rather than an absence of actual FDA clearance.

## Why This Denial Is Appealable

If the device is in fact FDA-cleared for the proposed indication and level, the denial is based on a factual error and should be reversed upon submission of the clearance documentation. If the use is off-label, the appeal must address Humana's off-label use policy and demonstrate that the use is supported by peer-reviewed medical literature and applicable clinical guideline organizations — but without relying on specific trial statistics, which should instead be cited from the published literature itself.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, submit a written internal appeal citing the specific clearance document. The plan must respond within mandated timeframes.
• External review: Available after a final internal denial; the external review window is generally approximately four months. An IRO will independently assess whether the denial was consistent with applicable coverage standards.
• Expedited review: Request if clinical delay poses serious health risk.

## Documentation to Gather

1. FDA clearance or approval letter — obtain the 510(k) clearance summary or PMA approval letter directly from the device manufacturer; confirm it covers the spine level and indication being treated. 2. Device labeling — the FDA-approved Instructions for Use (IFU) listing the cleared indications, contraindications, and patient-selection criteria. 3. Surgeon's operative plan — a letter confirming the procedure matches the cleared indication and that the correct device model and code were submitted. 4. Claim-code audit — have the billing department confirm the HCPCS/CPT code used aligns with the cleared device; resubmission with corrected coding resolves many of these denials without a formal appeal. 5. Clinical-necessity support — diagnosis documentation, imaging, and conservative-treatment history to address any secondary medical-necessity layer.

## Criteria-Mapping Structure

Obtain Humana's current coverage policy for ADR and its off-label-use policy if applicable. Map the clearance document directly to each requirement — device name, cleared indication, spine level, and patient-selection criteria from the IFU. Present this side-by-side table in the appeal letter so the reviewer can verify each element without ambiguity.